ArticleOncogene2026
SEC14L2 contributes to tumor progression by enhancing USP5-driven RBM3 deubiquitination in pancreatic ductal adenocarcinoma.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Pancreatic ductal adenocarcinoma (PDAC) persists as a highly lethal malignancy with a dire prognosis and scarce therapeutic advancements, highlighting an urgent demand for innovative prognostic markers and molecular targets. Herein, we identify Section 14-like lipid binding 2 (SEC14L2) as a pivotal oncogene in PDAC pathogenesis. Elevated SEC14L2 expression is established as a potent and consistent prognostic indicator, strongly associated with adverse clinical outcomes across multiple independent patient cohorts. Functional analyses confirm that SEC14L2 drives malignant progression by enhancing proliferation and inhibiting apoptosis in PDAC cells. Mechanistically, we elucidate that SEC14L2 orchestrates the recruitment of ubiquitin-specific-processing protease 5 (USP5) to RNA-binding motif protein 3 (RBM3). This interaction facilitates USP5-mediated deubiquitination of RBM3 at lysine 84, specifically cleaving K48-linked polyubiquitin chains, which consequently stabilizes the RBM3 protein. The accumulated RBM3 then augments the mRNA stability of doublecortin-like kinase 1 (DCLK1), a recognized mediator of tumorigenesis. Furthermore, we uncover that the transcription factor SP1 acts as a key upstream regulator, directly governing the transcriptional activation of SEC14L2 and fostering its frequent upregulation in PDAC. Our findings delineate a novel SP1/SEC14L2/USP5/RBM3/DCLK1 signaling axis that critically propels PDAC progression, thereby nominating SEC14L2 as a compelling therapeutic target for this devastating disease.
Indexed as
Identifiers
42649370What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.